Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer

References

• Nele Van Der Steen RJH, Dekker H, Van Meerloo J, et al. Resistance to crizotinib in a cMET gene amplified tumor cell line is associated with impaired sequestration of crizotinib in lysosomes. J Mol Clin Med. 2018;1(2):99–106.
   Google Scholar
• Baker MJ, Cooke M, Kazanietz MG. Nuclear PKCι-ECT2-Rac1 and ribosome biogenesis: a novel axis in lung tumorigenesis. Cancer Cell. 2017;31(2):167–169.
   PubMed Web of Science ®Google Scholar
• Richard PJ, Rengan R. Oligometastatic non-small-cell lung cancer: current treatment strategies. Lung Cancer (Auckl)). 2016;7:129–140.
   PubMedGoogle Scholar
• Lakshmi SP, Reddy AT, Banno A, et al. PPAR agonists for the prevention and treatment of lung cancer. PPAR Res. 2017;2017:8252796.
   PubMed Web of Science ®Google Scholar
• Bond DA, Dunavin N, Otterson GA. Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease. Cancer Invest. 2015;33(3):86–88.
   PubMed Web of Science ®Google Scholar
• Neve RM, Parmar H, Amend C, et al. Identification of an epithelial-specific enhancer regulating ESX expression. Gene. 2006;367:118–125.
   PubMed Web of Science ®Google Scholar
• Oliver JR, Kushwah R, Hu J. Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease. Lab Invest. 2012;92(3):320–330.
   PubMed Web of Science ®Google Scholar
• Shatnawi A, Norris JD, Chaveroux C, et al. ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014;33(7):862–871.
   PubMed Web of Science ®Google Scholar
• Nakarai C, Osawa K, Matsubara N, et al. Significance of ELF3 mRNA expression for detection of lymph node metastases of colorectal cancer. Anticancer Res. 2012;32:3753–3758.
   PubMed Web of Science ®Google Scholar
• Prescott JD, Koto KS, Singh M, et al. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol. 2004;24(12):5548–5564.
   PubMed Web of Science ®Google Scholar
• Yeung T-L, Leung CS, Wong K-K, et al. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 2017;8(10):16951–16963.
   PubMedGoogle Scholar
• Iwai S, Amekawa S, Yomogida K, et al. ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Oral Dis. 2008;14(2):144–149.
   PubMed Web of Science ®Google Scholar
• Wang H, Yu Z, Huo S, et al. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 2018;94:98–106.
   PubMed Web of Science ®Google Scholar
• Mégnin-Chanet F, Bollet MA, Hall J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci. 2010;67(21):3649–3662.
   PubMed Web of Science ®Google Scholar
• Metzger MJ, Stoddard BL, Monnat RJ. Jr. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks. DNA Repair (Amst). 2013;12(7):529–534.
   PubMed Web of Science ®Google Scholar
• He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin. 2010;31(9):1172–1180.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–1078.
   PubMed Web of Science ®Google Scholar
• Montoni A, Robu M, Pouliot E, et al. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol. 2013;4:18–18.
   PubMed Web of Science ®Google Scholar
• Carey JPW, Karakas C, Bui T, et al. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer. Cancer Res. 2018;78(3):742–757.
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Cooper T, Stanley JA, et al. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PloS One. 2012;7(10):e46614.
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769–1792.
   PubMed Web of Science ®Google Scholar
• Bonanno L, Favaretto A, Rosell R. Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Res. 2014;34(1):493–501.
   PubMedGoogle Scholar
• Henneman L, van Miltenburg MH, Michalak EM, et al. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc Natl Acad Sci USA. 2015;112(27):8409–8414.
   PubMed Web of Science ®Google Scholar
• Wilson C, Nicholes K, Bustos D, et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget. 2014;5(17):7328–7341.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wei Y, Wang L, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014;16(9):864–875.
   PubMed Web of Science ®Google Scholar
• Sayan AE, Griffiths TR, Pal R, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA. 2009;106(35):14884–14889.
   PubMed Web of Science ®Google Scholar
• Balaji K, Vijayaraghavan S, Diao L, et al. AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers. Mol Cancer Res. 2017;15(1):45–58.
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–5868.
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. 2010;2010:1–9.
   Google Scholar
• Gildemeister O, Sage J, Knight K. Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C. J Biol Chem. 2009;284(46):31945–31952.
   PubMed Web of Science ®Google Scholar
• Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203–1210.
   PubMed Web of Science ®Google Scholar
• Parvin S, Ramirez-Labrada A, Aumann S, et al. LMO2 confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell. 2019;36(3):237–249.e236.
   PubMed Web of Science ®Google Scholar
• Sun C, Yin J, Fang Y, et al. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell. 2018;33(3):401–416.e408.
   PubMed Web of Science ®Google Scholar
• Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15(9):564–576.
   PubMed Web of Science ®Google Scholar
• Szanto A, Hellebrand EE, Bognar Z, et al. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol. 2009;77(8):1348–1357.
   PubMed Web of Science ®Google Scholar
• De P, Sun Y, Carlson JH, et al. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia (New York, NY). 2014;16(1):43–72.
   PubMed Web of Science ®Google Scholar
• Leung AW, de Silva T, Bally MB, et al. Synthetic lethality in lung cancer and translation to clinical therapies. Mol Cancer. 2016;15(1):61.
   PubMedGoogle Scholar